Samsara Stock And 2 Founder Led Picks For AI Powered Operations

Founder led companies can offer something that quarterly hired executives often lack: a long term mindset backed by personal reputation and ownership. With inflation data easing in some regions, rate expectations shifting and energy tensions keeping volatility alive, many investors are looking for business leaders who stay focused through noise. This Founder-Led Companies screener filters for stocks where the person at the top has real skin in the game and a history of building rather than just managing. In this article, you will see three of the strongest candidates from the screener to consider for further research.

Standard Nuclear (STDN)

Overview: Standard Nuclear is a US based advanced nuclear fuel company that designs, engineers, and manufactures TRISO fuel for small modular reactors, microreactors, and federal programs using HALEU fueled demonstration and mobile microreactor systems.

Operations: Standard Nuclear currently generates about US$3.36m in revenue from TRISO production, almost entirely from customers in the United States.

Market Cap: US$1.67b

Standard Nuclear gives founder focused investors exposure to a pure play on advanced nuclear fuel at a very early stage, with revenue still small at about US$3m and the company reporting a loss of US$7.71m in the first quarter of 2026. The balance sheet is highly stressed, with negative equity, a very high P/B ratio and all liabilities coming from external borrowings, while return on equity is currently negative. However, the company has already been selected by the US Department of Energy for negotiations around surplus plutonium utilization, raised US$150m in its NYSE IPO, and signed a fuel recycling MOU with Oklo. The mix of government ties, new board members with deep nuclear experience and tight post IPO lock ups is where the real interest lies.

Standard Nuclear is trying to turn government backed nuclear fuel projects into a full business while carrying a highly stressed balance sheet, so it is worth reading the Standard Nuclear financial health report

Samsara (IOT)

Overview: Samsara is an IoT and software company that connects data from vehicles, equipment, and industrial sites into a single AI powered platform so customers can monitor fleets, improve safety, manage assets, and automate everyday operations across sectors such as transportation, logistics, construction, and public services.

Operations: Samsara generates about US$1.73b in revenue from software and programming, with around US$1.48b coming from the United States and US$255.55m from other regions.

Market Cap: US$22.33b

Samsara gives founder focused investors exposure to the digitisation of physical operations, with an ARR base of US$1.89b and thousands of customers using its AI powered cameras and sensors to cut accidents and losses. The company is now profitable, posting GAAP net income of US$44.51m in Q1 2026 and guiding to a profitable full fiscal 2027, while revenue growth forecasts around the high teens and strong net revenue retention above 115% point to ongoing customer expansion. On the other hand, the stock trades at a rich P/S multiple, insider selling has picked up, and all liabilities are funded by external borrowing, which lifts funding risk. How investors weigh that trade off against Samsara’s data moat and AI product momentum is where the real debate starts.

Samsara’s accelerating AI story is rubbing up against a rich revenue multiple and rising insider selling, so it is worth reading the analysis report for Samsara to see what might be masking the real risk reward setup.

GH Research (GHRS)

Overview: GH Research is a Dublin based clinical stage biopharmaceutical company developing mebufotenin based therapies, led by its inhaled product GH001, for hard to treat forms of depression including treatment resistant depression, bipolar II disorder and postpartum depression, with an intravenous candidate GH002 targeting broader psychiatric and neurological conditions.

Market Cap: US$2.0b

GH Research is on many investors’ radars because it sits at the intersection of psychedelic medicine and severe depression, an area where traditional treatments often fall short. Early data for GH001 in postpartum depression showed the primary endpoint was met, with large MADRS score reductions by Day 8 and all patients in remission at that point. This is rare to see this early in a program. At the same time, the company is still pre revenue, reporting a net loss of US$18.97m in Q1 2026 and carrying a high P/B multiple and funding risk, as all liabilities come from external borrowing. With the FDA finalizing psychedelics guidance and GH Research raising US$117.5m in fresh equity, a key question is how these trial results and regulatory shifts could reshape expectations for this US$2.0b stock.

GH Research sits where fast moving depression trial data meets a complex psychedelics rulebook. Before assumptions harden, read the analyst forecasts for GH Research to see what the latest guidance could be hinting at.

The three founder led stocks covered here are just a starting point, as the full Simply Wall St screener has identified 349 more companies where founders still set the tone and the equity story is closely tied to their personal stakes and track records, all captured inside the Founder-Led Companies screener. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter to you, so you can focus on founder led businesses that best fit your own highest conviction ideas.

Take Control of Your Investment Journey

If GH Research or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Momentum Flies?

Some of the sharpest breakouts start quietly, then move fast while most investors are caught looking elsewhere. Scan these fresh ideas before the crowd closes the gap and consider them while they are still less widely followed.

• Explore established payouts that may keep cash flowing with a curated set of 8 dividend fortresses, while yields remain less widely noticed for now.
• Look for potential infrastructure opportunities by scanning 54 AI infrastructure stocks while AI-related themes are still being evaluated by the market.
• Consider future-facing materials exposure with a focused pool of 29 best rare earth metal stocks before more investors focus on the same supply dynamics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com